Tags

Type your tag names separated by a space and hit enter

Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood.
Epilepsy Behav. 2010 Feb; 17(2):193-8.EB

Abstract

Several recent studies have shown that levetiracetam (LEV) can be beneficial in the treatment of children with typical rolandic epilepsy (RE). Reports about the effectiveness of LEV in the treatment of children with the less benign variants in the spectrum of "benign" idiopathic focal epilepsies are still rare. Little is known about the effect of LEV on interictal epileptiform discharges in these syndromes. We report on LEV therapy in 32 children (mean age: 10.6 years, range: 4-14) with RE or variants like atypical benign idiopathic partial epilepsy of childhood (ABIPEC), Landau-Kleffner syndrome (LKS), and continuous spikes and waves during sleep (CSWS) and in children with benign idiopathic focal epileptiform discharges of childhood (BIFEDC). Cognitive and behavioral problems, not seizures, may be related to the pathological EEG. Patients with a reduction in seizure frequency >50% and/or reduction in BIFEDC >90% 3 months after having started LEV therapy were defined as responders. The average dose of LEV was 39 mg/kg body wt per day; LEV was given in monotherapy to 31.3% of the patients. Overall, 20 of 32 patients (62.5%) did benefit: 12 of 24 patients had a >50% reduction in seizure frequency; 2 of 24 patients (8.3%) were completely seizure free; 18 of 32 patients (56.3%) had a >90% reduction in BIFEDC (including CSWS); 6 of 32 (18.8%) had an EEG completely free of epileptiform discharges; and 17 of 32 (53.1%) showed improvement in cognition and/or language functions and/or behavior. Surprisingly, LEV tended to be more helpful in atypical rolandic epilepsies and other variants.

Authors+Show Affiliations

Clinic for Neuropediatrics and Neurologic Rehabilitation, Epilepsy Centre for Children and Young People, Vogtareuth, Germany. celina1@gmx.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20045383

Citation

von Stülpnagel, C, et al. "Levetiracetam as Add-on Therapy in Different Subgroups of "benign" Idiopathic Focal Epilepsies in Childhood." Epilepsy & Behavior : E&B, vol. 17, no. 2, 2010, pp. 193-8.
von Stülpnagel C, Kluger G, Leiz S, et al. Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood. Epilepsy Behav. 2010;17(2):193-8.
von Stülpnagel, C., Kluger, G., Leiz, S., & Holthausen, H. (2010). Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood. Epilepsy & Behavior : E&B, 17(2), 193-8. https://doi.org/10.1016/j.yebeh.2009.10.024
von Stülpnagel C, et al. Levetiracetam as Add-on Therapy in Different Subgroups of "benign" Idiopathic Focal Epilepsies in Childhood. Epilepsy Behav. 2010;17(2):193-8. PubMed PMID: 20045383.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levetiracetam as add-on therapy in different subgroups of "benign" idiopathic focal epilepsies in childhood. AU - von Stülpnagel,C, AU - Kluger,G, AU - Leiz,S, AU - Holthausen,H, Y1 - 2009/12/31/ PY - 2009/06/09/received PY - 2009/10/30/revised PY - 2009/10/31/accepted PY - 2010/1/5/entrez PY - 2010/1/5/pubmed PY - 2010/5/22/medline SP - 193 EP - 8 JF - Epilepsy & behavior : E&B JO - Epilepsy Behav VL - 17 IS - 2 N2 - Several recent studies have shown that levetiracetam (LEV) can be beneficial in the treatment of children with typical rolandic epilepsy (RE). Reports about the effectiveness of LEV in the treatment of children with the less benign variants in the spectrum of "benign" idiopathic focal epilepsies are still rare. Little is known about the effect of LEV on interictal epileptiform discharges in these syndromes. We report on LEV therapy in 32 children (mean age: 10.6 years, range: 4-14) with RE or variants like atypical benign idiopathic partial epilepsy of childhood (ABIPEC), Landau-Kleffner syndrome (LKS), and continuous spikes and waves during sleep (CSWS) and in children with benign idiopathic focal epileptiform discharges of childhood (BIFEDC). Cognitive and behavioral problems, not seizures, may be related to the pathological EEG. Patients with a reduction in seizure frequency >50% and/or reduction in BIFEDC >90% 3 months after having started LEV therapy were defined as responders. The average dose of LEV was 39 mg/kg body wt per day; LEV was given in monotherapy to 31.3% of the patients. Overall, 20 of 32 patients (62.5%) did benefit: 12 of 24 patients had a >50% reduction in seizure frequency; 2 of 24 patients (8.3%) were completely seizure free; 18 of 32 patients (56.3%) had a >90% reduction in BIFEDC (including CSWS); 6 of 32 (18.8%) had an EEG completely free of epileptiform discharges; and 17 of 32 (53.1%) showed improvement in cognition and/or language functions and/or behavior. Surprisingly, LEV tended to be more helpful in atypical rolandic epilepsies and other variants. SN - 1525-5069 UR - https://www.unboundmedicine.com/medline/citation/20045383/Levetiracetam_as_add_on_therapy_in_different_subgroups_of_"benign"_idiopathic_focal_epilepsies_in_childhood_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1525-5050(09)00606-4 DB - PRIME DP - Unbound Medicine ER -